Overview

This trial is active, not recruiting.

Conditions refractory multiple myeloma, stage i multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma
Treatments vismodegib, pharmacological study, laboratory biomarker analysis
Phase phase 1
Target PTCH1
Sponsor National Cancer Institute (NCI)
Start date December 2010
End date October 2014
Trial size 38 participants
Trial identifier NCT01330173, 8414, CDR0000691708, J1067, JHOC-J1067, NA_00040967, NCI-2012-02914, P30CA006973, U01CA070095

Summary

This phase I trial studies how well vismodegib after stem cell transplant works in treating patients with high-risk first remission or relapsed multiple myeloma. Vismodegib may slow the growth of cancer cells. Giving vismodegib after autologous stem cell transplant may kill more multiple myeloma cells.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
vismodegib Erivedge
Given PO
pharmacological study pharmacological studies
Correlative studies
laboratory biomarker analysis
Correlative studies

Primary Outcomes

Measure
Change in MM CSC counts
time frame: Baseline to 6 months

Secondary Outcomes

Measure
Pharmacokinetics of vismodegib
time frame: Days 1 and 15
Pharmacodynamics of vismodegib
time frame: Up to 4 weeks after completion of study treatment
Time to progression
time frame: From treatment initiation to the date of progression, assessed up to 4 weeks after completion of study treatment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients must have histologically or cytologically confirmed multiple myeloma meeting criteria with symptomatic disease requiring treatment; patients considered to have high risk disease (defined as chromosome 13 deletion by cytogenetics; t(4;14), t(14;16) or 17p deletion by fluorescence in situ hybridization [FISH], B2-M > 5.5 g/dL, immunoglobulin A [IgA] phenotype) in first remission (>= partial remission [PR]) or patients with relapsed myeloma responding to salvage therapy (>= PR) based on the International Uniform Response Criteria are eligible - Patients must have measurable disease utilizing serum or urine protein electrophoresis or serum kappa / lambda light chain assay - Patients must be planning to proceed to single autologous transplantation according to institutional standards and must receive this transplantation prior to implementation of GDC-0449 - Concomitant bisphosphonate use is allowed as clinically indicated - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) - Life expectancy of greater than 6 months - Women of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to GDC-0449 treatment, for the duration of study participation, and for at least 12 months post-treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of GDC-0449 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of GDC-0449; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing GDC-0449, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient understands of GDC-0449 cause serious or life-threatening birth defects - Women of childbearing potential are defined as follows: - Patients with regular menses - Patients with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding - Women who have had a tubal ligation - Women are considered not to be of childbearing potential for the following reasons: - The patient has undergone hysterectomy and/or bilateral oophorectomy - The patient is post-menopausal defined by amenorrhea for at least 1 year in a women - Human immunodeficiency virus (HIV)-positive patients without a prior acquired immune deficiency syndrome (AIDS)-defining illness and a CD4 count 400/millimeter^3 and either do not require anti-HIV therapy or are taking anti-HIV therapy that would not interfere with GDC-0449 (e.g. not taking zidovudine, protease inhibitors or non-nucleoside reverse transcriptase inhibitors) are eligible - Ability to understand and the willingness to sign a written informed consent document

Additional Information

Official title A Phase 1b Study of GDC-0449 Following Autologous Transplantation in Patients With High Risk First Remission or Relapsed Multiple Myeloma
Principal investigator Carol Huff
Description PRIMARY OBJECTIVES: I. To determine if GDC-0449 (vismodegib) is able to reduce myeloma cancer stem cells (CSC) when given to patients with multiple myeloma (MM) following autologous stem cell transplantation. SECONDARY OBJECTIVES: I. To determine whether GDC-0449 is inhibiting the hedgehog (Hh) pathway in patients with MM following autologous transplantation by measuring downstream targets of Hh using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) on plasma cells and MM CSC obtained from blood and bone marrow of patients undergoing treatment. II. To determine whether changes in MM CSC as measured by clonogenic assays on bone marrow are seen in response to GDC-0449 and whether these changes predict recurrence. III. To determine whether changes in MM CSC can be measured with similar or better accuracy using peripheral blood flow cytometry as compared to bone marrow clonogenic assays. IV. To determine the safety and toxicity profile for treatment with GDC-0449 following autologous transplantation in patients with high risk or relapsed MM. V. To characterize the pharmacokinetics (PK) of GDC-0449 (total and unbound) at steady-state and correlate this with pharmacodynamic (PD) endpoints. VI. To determine the one year progression free survival for patients given GDC-0449 following autologous transplantation. OUTLINE: Patients receive vismodegib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. After completion of treatment, patients are followed up for 4 weeks.
Trial information was received from ClinicalTrials.gov and was last updated in September 2014.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).